FDA Brief

Warning letters Drugs

FDA warning letter to

Sangleaf Pharm., Co. Ltd.

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

Sangleaf Pharm failed to give FDA requested records for OTC drugs, including children's toothpaste, at risk of DEG/EG contamination.

What happened

FDA reviewed import records and saw multiple drug shipments that named Sangleaf Pharm., Co., Ltd. as the manufacturer. FDA sent an electronic request for records on December 14, 2022, sent a second request on January 11, 2023, tried to call the registered U.S. agent on January 26, 2023, and sent a follow-up written request on January 27, 2023. Delivery was confirmed, but the company did not respond or provide the records.

What FDA found

  1. The company did not respond to FDA's requests for records about the drugs it registered as manufacturing.

    section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
  2. Refusing to permit access to or copying of records required by FDA is a prohibited act.

    section 301(e) of the FD&C Act (21 U.S.C. 331(e))

What FDA wants

Respond in writing within 15 working days, identify the reply with FEI #3012845410 and ATTN Matthew R. Dionne, Pharm.D, Compliance Officer. The company may provide information for FDA to consider and/or request an FDA inspection.

Who should pay attention

  • U.S. importers and distributors of Sangleaf drug products
  • companies that buy OTC drugs or children's toothpaste from this contract manufacturer
  • brands using foreign manufacturers with high-risk DEG/EG ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  4. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk